LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
ZKH
ZKH Group Limited
There isn't enough reported data to score ZKH yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ZKH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Stable | |
| Unavailable |
ZKH's cash flow is currently stable, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
ZKH PE Valuation
ZKH has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ZKH Forward outlook
There aren't enough analyst estimates for ZKH to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
ZKH Earnings Per Share
ZKH has the edge over LCID in the latest year-over-year earnings comparison.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over ZKH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
ZKH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $365.7M | +12% |
| Q1 2026 | $317.2M | +9.2% |
| Q4 2025 | $383.8M | -70% |
| Q3 2025 | $349.4M | +2.1% |
| Q2 2025 | $325.2M | -3.7% |
| Q1 2025 | $290.4M | +4% |
| Q4 2024 | $1.3B | +245% |
| Q3 2024 | $342.3M | +0.7% |
ZKH's revenue is recovering but still below its 2024 peak: $366M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.2% | +3.5 points |
| Q1 2026 | -1.1% | +3.1 points |
| Q4 2025 | -1.1% | +2.7 points |
| Q3 2025 | -1.4% | +3.2 points |
| Q2 2025 | -3.3% | -0.1 points |
| Q1 2025 | -4.2% | +2.8 points |
| Q4 2024 | -3.8% | -3.6 points |
| Q3 2024 | -4.6% | +0.7 points |
ZKH has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
ZKH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | +$12.5M |
| Q3 2024 | $0 | $0 |
ZKH's free cash flow was $0 over the past year, against $0 the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
ZKH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -59K shares |
| 1 year | -1.6% | -72.8K shares |
| 3 years | +386% | +3.7M shares |
ZKH has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ZKH Net Leverage
ZKH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ZKH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 19.8 | Oversold |
| Stochastic | 6.5 | Oversold |
ZKH's weekly RSI is 20 (oversold) and its Stochastic is 7 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
ZKH PE vs Consumer Cyclical Sector
ZKH has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
ZKH has stronger trend alignment. LCID is above 0 of 5 weekly averages versus ZKH above 0 of 4.
ZKH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.91 | 33% below |
| 20 week MA | $2.48 | 48% below |
| 50 week MA | $2.88 | 56% below |
| 100 week MA | $3.02 | 58% below |
ZKH is in a downtrend: it's below all four of its weekly moving averages, and 58% below its 100-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
ZKH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $15.5 | $16.3 | +5.2% |
| 2024 | $16.3 | $3.35 | -79% |
| 2025 | $3.35 | $3.65 | +9% |
| 2026 YTD | $3.65 | $1.28 | -65% |
ZKH has the edge over LCID on returns for 2026, with the stronger performance.